News 2019

Acacia Pharma reports positive cardiac safety data for BARHEMSYS™

January 22, 2019 – Cambridge, UK and Indianapolis, US - Acacia Pharma (EURONEXT: ACPH) announces results from its latest study of BARHEMSYS™, its anti-emetic currently under FDA review for the management of post-operative nausea & vomiting (PONV). The study did not find a significant risk for heart…

Related to: Acacia Pharma

Gilde Healthcare leads USD 77 million financing round of hypertension company Ablative Solutions

January 3, 2019 – Ablative Solutions today announced the first close of its USD 77 million Series D funding round. The round was led by Gilde Healthcare and co-led by existing investor BioStar Ventures and an undisclosed new strategic corporate investor.